Table 1.
Demographic and clinical characteristics of sample (N=52)
| Variables | Participants | P-value | |
|---|---|---|---|
| XRT subjects (N=35) | Controls (N=17) | ||
| Mean (± SEM) or N (%) | Mean (± SEM) or N (%) | ||
| Mean age, years | 67.7 (±1.4) | 63.7 (±1.7) | 0.09 |
| Ethnicity: | |||
| Caucasian | 21 (60%) | 15 (88%) | |
| African-American | 14 (40%) | 1 (6%) | |
| Asian | 1 (6%) | ||
| Marital status | |||
| Married | 22 (63%) | 15 (88%) | |
| Widowed | 6 (17%) | ||
| Single | 3 (9%) | ||
| Divorced/separated | 4 (11%) | 2 (12%) | |
| Employment status | |||
| Employed | 14 (40%) | 13 (76%) | |
| Retired | 19 (54%) | 4 (24%) | |
| Disabled | 2 (6%) | ||
| T-stage | |||
| T1c | 31 (88%) | 16 (94%) | |
| T2a-c | 2 (6%) | 1 (6%) | |
| T3a | 2 (6%) | ||
| Gleason Score | |||
| 7 Jun | 21 (60%) | 16 (94%) | |
| 10 Aug | 14 (40%) | 1 (6%) | |
| Karnofsky performance scale | 88.6 (±0.8) | 90.0 (±0.8) | 0.62 |
| PSA (ng/mL) | |||
| Baseline | 12.6 (±2.12) | 4.7 (±0.6) | 0.02 |
| Endpoint | 0.7 (±0.95) | 4.2 (±0.6) | 0.01 |
| Hemoglobin (mg/dL) | 0.46 | ||
| Baseline | 14.4 (±0.3) | 15.3 (±0.7) | |
| Endpoint | 13.9 (±0.4) | ||
| Hematocrit (%) | 0.22 | ||
| Baseline | 43.4 (±0.8) | 45.6 (±1.7) | |
| Endpoint | 41.1 (±0.9) | ||
| Depression (HAM-D) | |||
| Baseline | 1.3 (±0.3) | 0.5 (±0.3) | 0.12 |
| Endpoint | 1.2 (±0.3) | 0.2 (±0.1) | 0.09 |
| Total EBRT dosage (Gy) | |||
| 79.2–81 | 24 (68%) | None | |
| 100 | 11 (32%) | ||
Notes: Controls are men with nonmetastatic prostate cancer and not receiving any treatment are placed in active surveillance.
Abbreviations: SEM, standard error of the mean; PSA, prostate- specific antigen; HAM-D, Hamilton Depression Rating Scale; XRT, external beam radiation therapy.